Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of Windsor

$30,000.00

Development of Lateral Flow Assays to detect neutralizing antibodies to monitor immunity status of Canadians _x000d_ _x000d_

EF 2020-21

Résumé
Audacia Biosciences, a Canadian Biotechnology company, and Dr. Trant's research team at the University of Windsor, will be collaborating on generating a new, simple to use, mass producible, and fast-response, COVID-19 test to determine who is immune from the disease. Immunity to COVID-19 can arise either through vaccination or through prior exposure to SARS-CoV-2, the virus that causes the disease, but we are learning that reinfection is possible, and we know that vaccines will not be 100% effective. Coronaviruses in general do not generate a long-lasting immune response, and it is unlikely that SARS-CoV-2 will be an exception. This means that as the virus continues to spread in the population in the coming years, and especially once vaccines are deployed, we will want to monitor our immune status to determine if we need a booster shot, or need a different vaccine. Most vaccines in clinical trials will work by getting our bodies to initiate an immune response against the virus' spike protein, partially through the presence of neutralizing antibodies that enrobe the Spike and prevent it from helping the virus enter our cells. The research collaboration is looking to take advantage of this common method of action to develop a test, similar in concept to an at-home pregnancy test (that also uses antibodies), that can determine whether and how many of these protective antibodies are circulating. This will be essential for us to return to greater normalcy and will help us protect more vulnerable members of society. This project, consequently, not only advances the business interests of a Canadian company to create a globally-relevant test, but also provides a very important social benefit to Canada.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
558269-2020
Name nom
Trant, John
Department département
Chemistry and Biochemistry
Organization id
37
Institution établissement
University of Windsor
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
30000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Development of Lateral Flow Assays to detect neutralizing antibodies to monitor immunity status of Canadians _x000d_ _x000d_
Keyword
NSERC
Application summary
Audacia Biosciences, a Canadian Biotechnology company, and Dr. Trant's research team at the University of Windsor, will be collaborating on generating a new, simple to use, mass producible, and fast-response, COVID-19 test to determine who is immune from the disease. Immunity to COVID-19 can arise either through vaccination or through prior exposure to SARS-CoV-2, the virus that causes the disease, but we are learning that reinfection is possible, and we know that vaccines will not be 100% effective. Coronaviruses in general do not generate a long-lasting immune response, and it is unlikely that SARS-CoV-2 will be an exception. This means that as the virus continues to spread in the population in the coming years, and especially once vaccines are deployed, we will want to monitor our immune status to determine if we need a booster shot, or need a different vaccine. Most vaccines in clinical trials will work by getting our bodies to initiate an immune response against the virus' spike protein, partially through the presence of neutralizing antibodies that enrobe the Spike and prevent it from helping the virus enter our cells. The research collaboration is looking to take advantage of this common method of action to develop a test, similar in concept to an at-home pregnancy test (that also uses antibodies), that can determine whether and how many of these protective antibodies are circulating. This will be essential for us to return to greater normalcy and will help us protect more vulnerable members of society. This project, consequently, not only advances the business interests of a Canadian company to create a globally-relevant test, but also provides a very important social benefit to Canada.